Fig. 1: Brusatol sensitizes endometrial cancer cell to progestin by downregulating the expression of NRF2 and its downstream genes. | Laboratory Investigation

Fig. 1: Brusatol sensitizes endometrial cancer cell to progestin by downregulating the expression of NRF2 and its downstream genes.

From: Brusatol sensitizes endometrial hyperplasia and cancer to progestin by suppressing NRF2-TET1-AKR1C1-mediated progestin metabolism

Fig. 1: Brusatol sensitizes endometrial cancer cell to progestin by downregulating the expression of NRF2 and its downstream genes.The alternative text for this image may have been generated using AI.

A Ishikawa and ECC1 cells were treated with the indicated doses of brusatol for 48 h, and cell viability was estimated by the CCK8 assay (upper panel). The expression of NRF2 related protein was detected by immunoblotting (lower panel). *p < 0.05 compared with the blank control. B Ishikawa and ECC1 cells were treated with 20 nM brusatol for the indicated time and the expression levels of NRF2 and its downstream proteins were analyzed by immunoblotting. C Ishikawa cells were treated with the MPA (20 μM) or brusatol (20 nM) alone, or combined MPA and brusatol for the indicated time, and the CCK8 assay was performed. *p < 0.05. D A stable cell line with high levels of NRF2 was established, and its response to progestin was evaluated by a CCK8 assay. *p < 0.05. E The expression patterns of NRF2, TET1 and AKR1C1 were detected by immunoblotting.

Back to article page